China mulls fixed reimbursement by active ingredient
This article was originally published in Scrip
Executive Summary
China's National Development and Reform Commission (NDRC) is considering additional policy steps in the drug pricing arena following on from a major survey of product costs and prices that it initiated in July, Scrip understands.